The HER2CLIMB-02 study has shown that the combination of T-DM1 and tucatinib significantly enhances PFS among patients with HER2-positive advanced breast cancer, while OS data remain under ongoing evaluation[3]. Here, ERBB2 is linked to breast carcinoma.